Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has...

VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer

This clinical trial will investigate for the first time a combination of VB-111 with a checkpoint inhibitor. Pathology readouts are expected to shed light on the potential of VB-111 to turn “cold” colorectal tumors “hot.” TEL AVIV, Israel, Feb. 20, 2020 (GLOBE...
SEARCH FOR STUDIES